Skip to main content

Table 4 Acetaminophen Requirement in Patients Suffering with COVID-19

From: Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial

Dose of Acetaminophen

HCQ / placebo

HCQ / Levamisole

Total

N (%)

N (%)

N (%)

Yes

12 (48.0)

10 (40.0)

22 (44.0)

500 mg tds for 2 days

1 (4.0)

0 (0.0)

1 (2.0)

500 mg tds for 3 days

3 (12.0)

8 (32.0)

11 (22.0)

500 mg tds for 8 days

1 (4.0)

0 (0.0)

1 (2.0)

500 mg tds for 10 days

1 (4.0)

0 (0.0)

1 (2.0)

500 mg tds for a week

5 (20.0)

2 (8.0)

7 (14.0)

500 mg tds for 2 weeks

1 (4.0)

0 (0.0)

1 (2.0)

No

13 (52.0)

15 (60.0)

28 (56.0)